Edition:
Deutschland

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

6.06USD
22 Feb 2018
Change (% chg)

$-0.05 (-0.82%)
Prev Close
$6.11
Open
$6.10
Day's High
$6.20
Day's Low
$6.06
Volume
12,272
Avg. Vol
160,704
52-wk High
$12.80
52-wk Low
$3.10

PTIE.OQ

Chart for PTIE.OQ

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)

Buy/Sell

Sell Hold Buy
2.00 Mean rating from 1 analysts

Overall

Beta: 2.17
Market Cap(Mil.): $28.03
Shares Outstanding(Mil.): 6.60
Dividend: --
Yield (%): --

BRIEF-Pain Therapeutics Signs On Demand Sales Agreement With JonesTrading Institutional Services

* PAIN THERAPEUTICS SAYS ON FEB 8, CO ENTERED INTO AN ATM CAPITAL ON DEMAND SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES LLC - SEC FILING

BRIEF-Pain Therapeutics Inc QTRLY ‍Net Loss Per Share $0.37​

* PAIN THERAPEUTICS INC QTRLY ‍NET LOSS PER SHARE $0.37​ Source text: [http://bit.ly/2nGTz7J] Further company coverage:

BRIEF-Pain Therapeutics Reports Positive Results From Nasal Abuse Potential Study With Remoxy

* PAIN THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM NASAL ABUSE POTENTIAL STUDY WITH REMOXY™

BRIEF-Pain Therapeutics Reports Positive Regulatory Meeting For Remoxy

* PAIN THERAPEUTICS REPORTS POSITIVE REGULATORY MEETING FOR REMOXY™

BRIEF-Pain therapeutics reports Q3 loss per share $0.40

* Pain therapeutics reports third quarter 2017 financial results

BRIEF-Pain Therapeutics announces upcoming meeting with FDA

* Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​

BRIEF-Pain Therapeutics announces successful Phase I clinical study for PTI-125

* Pain Therapeutics announces successful Phase I clinical study for PTI-125

BRIEF-National Institute on Drug Abuse awards Pain Therapeutics $2.2 mln grant

* National Institute on Drug Abuse awards Pain Therapeutics $2.2 million grant Source text for Eikon: Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.19%
Rohstoffe +0.14%
Industrie +0.10%
Konjunktur abhängige Waren & Dienstleistungen -0.08%
Konjunktur unabhängige Waren & Dienstleistungen +0.06%
Finanzindustrie -0.01%
Pharma +0.00%
Technologie +0.08%